QHQiang Huang

Qiang Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qiang Huang has a total of 191 co-authors. Here are the top co-authors by number of shared publications:

  • Gaochao Guo

    Department of Neurosurgery, Henan Provincial People,s Hospital; Zhengzhou University People,s Hospital; Cerebrovascular Disease Hospital

    10 shared publications
  • Yang Nan

    Tianjin Neurological Institute, Key Laboratory of Post-Neuro injury Neuro-repair and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin Medical University General Hospital, Tianjin 300052, China; Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 300052, China

    10 shared publications
  • Yalin Lu

    Tianjin Neurological Institute, Key Laboratory of Post-Neuroinjury Neuro-repair and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin Medical University General Hospital

    8 shared publications
  • Xingjie Chen

    Tianjin Neurological Institute, Key Laboratory of Post-Neuroinjury Neuro-repair and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin Medical University General Hospital

    7 shared publications
  • Kai Yu

    Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China

    6 shared publications
  • Yu Zhang

    Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China

    6 shared publications

Latest Publications

  • Open Access

    Phosphorylation of tumour suppressor Amotl2 by IKBKE kinase promotes YAP1 signalling, enhancing glioblastoma growth

    by Gaochao Guo, Yan Sun, Rujun Hong, Yalin Lu, Xingjie Chen, Liming Zhao, Chaoyue Li, Yang Liu, Qiang Huang

    Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE), a member of the serine/threonine kinase family, is an important oncogene in glioblastoma. IKBKE is involved in the progression of multiple tumours in glioblastoma (GBM), including tumour invasion, migration, and proliferation. Here, we report an IKBKE–angiomotin-like protein 2 (Amotl2)–yes-associated protein 1 (YAP1) axis in which IKBKE inhibits the protein expression of Amotl2, while Amotl2 regulates the nuclear transport of the YAP1 protein, which has been implicated in brain tumour development and progression. Data analysis of multiple IKBKE mRNA databases of glioma and immunohistochemical analysis of a tissue chip indicated that higher IKBKE expression was associated with higher malignancy and shorter survival in glioma patients. IKBKE downregulation significantly inhibited GBM cell proliferation and restrained tumour growth in a GBM mouse model. Moreover, IKBKE phosphorylates Amotl2, promoting Amotl2 ubiquitination and degradation, leading to YAP1 entry into the nucleus and the activation of downstream genes. In summary, our results are the first to show that IKBKE phosphorylates Amotl2 and that GBM cell proliferation is regulated by the IKBKE↑–Amotl2↓–YAP1↑ axis.

  • Open Access

    Diverse roles of SERPINE1 in regulating cellular proliferation and invasion

    by Wei Wang, Pengfei Zhao, Tian Wang, Weijing Wu, Jing Li, Qiang Huang, Jing Momo

    Serine protease inhibitor clade E member 1 (SERPINE1) is involved in various biological processes, but its role in promoting or suppressing tumorigenesis remains controversial. The present study focused on the effects of SERPINE1 downregulation on cell proliferation and invasion across three types of tumors to elucidate the underlying mechanisms. Based on data from an analysis of The Cancer Genome Atlas dataset, high SERPINE1 levels in patients with breast cancer and low‑grade glioma were associated with a poor prognosis, whereas elevated SERPINE1 expression in patients with skin cutaneous melanoma associated with improved outcomes. With respect to cell proliferation phenotypes, SERPINE1 knockdown increased xenograft growth and the proliferation of melanoma C918 cells by promoting cell cycle progression through the modulation of minichromosome maintenance complex component 3 and the activity of p53/SMAD3 regulators; conversely, SERPINE1 knockdown reduced the xenograft growth and proliferation of MDA‑MB‑231 breast cancer cells by decreasing the urokinase‑type plasminogen activator receptor‑mediated ERK/p38 activity ratio and similarly decreased proliferation in H4 glioma cells through an heat shock protein 90‑alpha (HSP90α)‑mediated reduction in the ERK/p38 activity ratio. Regarding invasion and metastasis, SERPINE1 knockdown consistently reduced invasion, matrix metalloproteinase (MMP) activity, and lung metastasis in both C918 and MDA‑MB‑231 cells but paradoxically increased invasion and MMP‑1 activity in H4 cells through the HSP90α‑p38‑MMP‑1 axis. Collectively, these findings suggested that SERPINE1 exerts diverse effects on cell proliferation and invasion through multiple regulatory mechanisms. These findings indicated that therapy targeting SERPINE1, which involves a comprehensive understanding of its diverse mechanisms of function, can increase treatment precision and reduce adverse reactions.


  • Open Access

    Expression of GSDMs in glioma and its influence on prognosis

    by Kai Liu, Shengli Chen, Tao Hu, Xuan Zhang, Qiang Huang

    Despite extensive research on therapeutic targets for glioma, progress has been limited by ineffective treatments. Our aim was to analyze gasdermin (GSDM) family expression, mutations, and clinical relevance in glioma to support clinical decision-making and risk assessment. Glioma specimens were procured from The Cancer Genome Atlas for the purpose of conducting gene expression profile interaction analysis and human protein mapping using various bioinformatics tools, including gene expression profiling interactive analysis, Human Protein Atlas, Kaplan–Meier plotters, cBioPorta, LinkedOmics, database for annotation, visualization and integrated discovery, and R Software. A statistically significant difference was observed with a P < .05. The investigation of mRNA expression levels of GSDM subtypes in 11,079 glioma tissues and 6942 normal brain tissues revealed significant differences, with GSDMA, GSDMD, and GSDME being elevated in glioma compared to normal tissues, while GSDMB showed lower expression. The analysis of mRNA expression levels for GSDM subtypes across 33 tumor and normal tissues showed significant differences in GSDMA, GSDMB, GSDMD, and GSDME. The expression of these genes varied significantly in different glioma subtypes, with higher levels noted in 1p19q non-deletion gliomas and IDH1 wild-type gliomas. Additionally, glioblastoma multiforme displayed increased GSDMA, GSDMD, and GSDME levels compared to other subtypes, with significant associations between gene expression and the clinical World Health Organization stage of gliomas. GSDMB, GSDMC, GSDMD, and GSDME were identified as independent prognostic factors affecting overall survival, with notable differences in recurrence-free survival among different expression groups. Mutation analysis revealed that expansion was the most common mutation in the GSDM family (7% of patients), primarily affecting GSDMD, which had a mutation rate of 5%. Correlation analyses highlighted both positive and negative relationships among GSDM members. Furthermore, enrichment analyses in the database for annotation, visualization and integrated discovery linked 173 associated genes to biological processes like pyroptosis and autophagy, along with involvement in the phagocytic and synaptic vesicle circulation pathways, suggesting that GSDMs may play critical roles in cell death mechanisms and autophagy in glioma, which requires further exploration. Overall, our results suggest a significant involvement of the GSDM group in the pathogenesis of glioma. GSDMB, GSDMC, GSDMD, and GSDME have been identified as potential prognostic and predictive markers for glioma, while GSDMs show promise as therapeutic targets for this type of brain tumor.

  • Open Access

    Case Report: The price of intraoperative cell salvage? - implantation metastases of meningioma in both lungs and left cubital fossa

    by Mengyao He, Shengping Yu, Wenjun Luo, Yu Zhang, Wenchao Liu, Cuiyun Sun, Qiang Huang

    Meningiomas are common Central Nervous System (CNS) tumors, typically benign, but they can occasionally metastasize or exhibit aggressive behavior. We present a case of meningioma with metastasis to unique sites (pulmonary and left cubital fossa) and intracranial recurrent progression. This case highlights challenges in managing recurrent and metastatic meningioma and the potential risks of intraoperative cell salvage (IOCS).

  • Open Access

    Potential Mechanism and Involvement of p120-Catenin in the Malignant Biology of Glioma

    by Leilei Wang, Jianshen Liang, Suzhen Ji, Chunlou Wang, Qiang Huang

    Objective : This study analyzed the influence of p120-catenin (catenin [cadherin-associated protein], delta 1 [CTNND1]) on the malignant characteristics of glioma and elucidated the potential underlying mechanism.Methods : The p120 expression level was assessed in the brain tissues of 42 glioma patients and 10 patients with epilepsy by using the immunohistochemical method. Meanwhile, quantitative polymerase chain reaction (QT-PCR) technology was employed to assess the expression of p120 in the brain tissues of 71 glioma patients and 13 epilepsy patients. LN229, U251, and U87 glioma cells were used for in vitro analysis and categorized into four treatment groups : siRNA-blank control (BC) group (no RNA sequence was transfected), siRNA-negative control (NC) group (transfected control RNA sequences with no effect), and siRNA-1 and siRNA-2 groups (two p120-specific interfering RNA transfection). p120 expression in these treatment groups was quantified by western blotting assay. The migratory and invasive capabilities of glioma cells were studied by wound healing assay and Transwell invasion assay, respectively, under different treatment conditions. MTT (3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide) assay and cell cycle and apoptosis assay were used to determine glioma cell proliferation and apoptosis, respectively. Enzymelabeled assay was performed to measure intracellular calcium ion concentration. Immunofluorescence assay was performed for determining microtubule formation and glioma cell distribution.Results : Brain tissues of the glioma group exhibited a remarkable increase in the p120 expression level as compared to brain tissues of the nontumor group (p<0.05). Furthermore, a strong positive correlation was noted between the malignancy degree in glioma brain tissues and p120 expression in Western blotting (r=0.906, p<0.0001) and QT-PCR (F=830.6, p<0.01). Compared to the BC and NC groups, the siRNA transfection groups showed a significant suppression in p120 expression in glioma cells (p<0.05), with a marked attenuation in the invasive, migratory, and proliferative capabilities of glioma cells as well as an increase in apoptotic potential (p<0.05). Enzyme-labeled assay showed a remarkable increase in calcium concentration in glioma cells after siRNA treatment. Immunofluorescence assay revealed that the microtubule formation ability of glioma cells reduced after siRNA treatment.Conclusion : p120 has a pivotal involvement in facilitating glioma cell invasion and proliferation by potentially modulating these processes through its involvement in microtubule formation and regulation of intracellular calcium ion levels.


  • NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells

    by Yu Zhang, Hao Yu, Mengyao He, Wenchao Liu, Shengyou Xiao, Xiangting Wang, Ping Huang, Qiang Huang

    NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells


  • Open Access

    Correction: TMEM158 promotes the proliferation and migration of glioma cells via STAT3 signaling in glioblastomas

    by Jiabo Li, Xuya Wang, Lulu Chen, Jinhao Zhang, Yiming Zhang, Xiao Ren, Jinzhang Sun, Xiaoguang Fan, Jikang Fan, Tao Li, et al.


  • IKBKE promotes the ZEB2-mediated EMT process by phosphorylating HMGA1a in glioblastoma

    by Yan Sun, Gaochao Guo, Yu Zhang, Xingjie Chen, Yalin Lu, Rujun Hong, Jinbiao Xiong, Jiabo Li, Xue Hu, Shuaishuai Wang, et al.


  • Prediction of outcomes for symptomatic spinal cavernous malformation surgery: a multicenter prospective clinical study

    by Tong Liu, Lichao Wang, Shizhong Zhang, Hao Han, Kangjie Du, Xin Chen, Zilong Zhao, Liwen Zhao, Jiapeng Xie, Lu Zhao, et al.

    Purpose Clinical outcome of spinal cavernous malformation (SCM) varies because of its unclear natural history, and reliable prognostic prediction model for SCM patients is limited. The aim of the present study was to investigate potential factors that predict one-year neurological status in postoperative patients with SCM. Methods This was a multicenter prospective observational study in consecutive patients with SCMs. SCMs treated microsurgically between January 2015 and January 2021 were included. Outcome was defined as the American Spinal Injury Association Impairment Scale (AIS) grade at one year after operation. Multivariable analyses were used to construct the best predictive model for patient outcomes. Results We identified 268 eligible SCM patients. Neurological outcome had worsened from preoperative baseline in 51 patients (19.0%) at one year. In the multivariable logistic regression, the best predictive model for unfavorable outcome included symptom duration ≥ 26 months (95% CI 2.80–16.96, P < 0.001), size ≤ 5 mm (95% CI 1.43–13.50, P = 0.010), complete intramedullary (95% CI 1.69–8.14, P = 0.001), subarachnoid hemorrhage (95% CI 2.92–12.57, P < 0.001), AIS B (95% CI 1.91–40.93, P = 0.005) and AIS C (95% CI 1.12–14.54, P = 0.033). Conclusions Admission size of the lesion, morphology, symptom duration, AIS grade and the presence of subarachnoid hemorrhage were strong outcome predictors regarding prognostication of neurological outcome in postoperative patients with SCMs. A decision to surgically remove a symptomatic SCM should be justified by systematic analysis of all factors potentially affecting outcome.


  • The expression of DLGAP5 associate with progression and prognosis in glioma

    by Du Kangjie, Zhang Yu, He Mengyao, Lu Yalin, Chen Xingjie, Yu Hao, Huang Qiang

    Glioma is the most common primary malignant tumor of the central nervous system and is related to poor clinical outcomes. At present, the standard treatment of glioma in clinical practice is to maximally remove the focus on the premise of protecting the neurological function, supplemented by postoperative chemotherapy and radiotherapy. However, after standard treatment, the prognosis of glioma patients is still not satisfactory. DLGAP5 has been shown to play an important role in the occurrence and progression of various tumors. This study examined the expression of DLGAP5 in glioma samples and its significance in predicting the prognosis of glioma patients. TCGA and CGGA datasets were used to explore the difference in DLGAP5 expression between glioma and normal central nervous system tissues and to investigate the prognostic value of DLGAP5 expression in glioma patients. The cBioPortal online analysis website was used to explore the gene mutations of DLGAP5 expressing in glioma. The String database and GEPIA online analysis website were used to perform Enrichment Analysis to explore the molecular mechanism of DLGAP5.In this study, we observed that DLGAP5 expression was upregulated in glioma tissues compared with normal CNS tissues and was negatively associated with the prognosis of glioma patients. DLGAP5 may affect the occurrence and progression of glioma mainly through gene mutation, gene amplification, and gene depth deletion. At the same time, the molecular inhibition of DLGAP5 may be related to the cell cycle and the p53 pathway. In conclusion, our findings suggested that DLGAP5 may be a therapeutic target and an independent prognostic indicator for glioma.